Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

176.59 -1.54 (-0.86%)
Streaming Delayed Price Updated: 11:57 AM EDT, Sep 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Why NYSE:JNJ provides a good dividend, while having solid fundamentals.
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
Via Chartmill
Is Johnson & Johnson Stock a Buy?
This healthcare blue chip is making all the right moves to reward shareholders. 
Via The Motley Fool
Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt
From Beasley Allen Law Firm
Via Business Wire
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
From Johnson & Johnson
Via Business Wire
The Latest Analyst Ratings For Johnson & Johnson
 
Via Benzinga
Unpacking the Latest Options Trading Trends in Johnson & Johnson
 
Via Benzinga
Competitor Analysis: Evaluating Johnson &amp; Johnson And Competitors In Pharmaceuticals Industry
 
Via Benzinga
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
Johnson & Johnson's Rybrevant (amivantamab) received FDA approval for use with standard chemotherapy in advanced non-small cell lung cancer with specific EGFR mutations. 
Via Benzinga
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic... 
Via Benzinga
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
Via Investor's Business Daily
2 Vanguard Index Funds Could Turn $400 Per Month Into $16,800 in Annual Dividend Income by Retirement
This two-step strategy could set investors up with a large sum of passive income in retirement. 
Via The Motley Fool
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the... 
Via Benzinga
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025. 
Via MarketBeat
Topics Economy
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
Should You Buy Novavax Stock After This Regulatory Win?
The biotech continues to earn important wins, but is it enough? 
Via The Motley Fool
How To Earn $500 A Month From Johnson & Johnson Stock
Johnson & Johnson offers an annual dividend yield of 3.01%. How can investors exploit its dividend yield to pocket a regular $500 monthly? 
Via Benzinga
Metals in Tampons: FDA Initiates New Safety Measures and Testing
The FDA is investigating concerns about metals in tampons after a 2024 study. The agency is conducting an internal study and reviewing existing literature to assess potential risks of metal exposure. 
Via Benzinga
Sony Music-Universal Music JV Hits Johnson & Johnson With Copyright Lawsuit Over Unlicensed Music Use Covering 80 Videos
Johnson & Johnson is facing a lawsuit from Associated Production Music for allegedly using unlicensed music in nearly 80 videos, potentially resulting in $12 million in damages under copyright law. 
Via Benzinga
Topics Lawsuit
Johnson & Johnson's Mid-Stage Lung Cancer Trial Reveals Fewer Infusion-Related Reactions
Johnson & Johnson announced promising Phase 2 SKIPPirr study results for Rybrevant in reducing infusion-related reactions in NSCLC patients. 
Via Benzinga
3 Safe Stocks with Safe Dividends for Your Portfolio
Secure your portfolio with stocks known for their stability and reliable dividend payouts, offering a sense of security during uncertain times. 
Via MarketBeat
Topics Economy
Is Hims & Hers Health the Next Teladoc?
Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic. 
Via The Motley Fool
2 Stocks That Are Passive Income Machines to Buy and Hold Forever
You can take these dividends straight to the bank. 
Via The Motley Fool
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential. 
Via Benzinga
Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
Kenvue Inc., owner of major brands like Tylenol, is poised for a technical knockout with a Golden Cross pattern and legal win. 
Via Benzinga
Dell, CoStar, PayPal And A Major Health Care Stock On CNBC's 'Final Trades'
Bill Baruch of Blue Line Capital named Dell Technologies Inc. his "final trade" on CNBC's "Halftime Report." 
Via Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
 
Via Benzinga
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Raises Talc Settlement Offer to $9B, Moves Closer to Settlement Victory
Johnson & Johnson boosts talc settlement offer to $9 billion, gaining support from key lawyer Allen Smith for quicker claimant payouts. 
Via Benzinga
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development. 
Via Benzinga
Topics Artificial Intelligence
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.